Guardant Health, Inc. (GH)

Guardant Health's stock price increased by 139.67% between February 4, 2025, and February 3, 2026. Recent events include participation in investor conferences, a study highlighting the effectiveness of the Guardant Reveal blood test, assessment of valuation following FDA approval and a new collaboration, insider selling transactions, and strong Q3 CY2025 results with a 38.5% year-on-year revenue increase.

Specific detailed information regarding the demand seasonality for Guardant Health's products and services is not explicitly provided. The healthcare sector, in general, can experience persistent defensive demand. The company has shown strong and accelerating revenue growth, suggesting consistent demand for its offerings, but no explicit seasonal patterns were identified.

Guardant Health, Inc. is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012, the company's mission is to advance cancer care by providing actionable data through non-invasive tests that utilize circulating tumor DNA. Key products include Guardant360, Guardant360 CDx, Guardant Reveal, Shield Test, and the LUNAR platform, among others. The company also provides development services, including companion diagnostic development, regulatory approval, clinical study setup, and technology licensing.

Guardant Health operates CLIA-certified, CAP-accredited laboratories within the United States. The company has expanded its service offerings across Europe and Asia through partnerships and regional laboratory certifications. Guardant Health has received regulatory approval for its Guardant360 CDx test in Japan, where the Japanese government has also approved national reimbursement for the test.

Guardant Health generally holds a "Moderate Buy" consensus rating from analysts and has demonstrated strong revenue growth. Positive events include FDA breakthrough designation, participation in the NIH Vanguard study, regulatory approval of Guardant360 CDx, and collaborations such as with Merck. Challenges include a lack of profitability, cash burn, significant long-term debt, negative margins, and insider selling activity.

Guardant Health, Inc. has a significant institutional ownership presence, with major holders including The Vanguard Group, Inc., BlackRock, Inc., and Baillie Gifford & Co. Institutions hold approximately 92.60% of the stock, while insiders hold about 6.10%. Other sources indicate institutional ownership around 31.79% to 47.60%, and individual/public investors holding a significant portion as well.